Recon: WHO adopts pandemic treaty, US unveils most-favored-nation pricing targets
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- RFK Jr. declared war on chronic disease. First comes the battle over priorities (STAT)
- US health authorities set most-favored-nation pricing targets (Reuters)
- Is Your UTI Pain Reliever Safe and Effective? (Bloomberg)
- IDEA ranks Lilly, AZ as biopharma's top innovators, inventors (Fierce Pharma)
- With U.S. absent, WHO adopts pandemic treaty aimed at improving vaccine access (STAT)
- Robert F. Kennedy Jr calls WHO 'moribund', urges others to quit (Reuters)
- WHO says vaccine-derived poliovirus detected in Papua New Guinea (Reuters)
- MORE Details On MHRA’s Online Platform For Post Market Surveillance (MedTech Insight)
- Tourmaline drug cuts inflammation tied to heart disease (STAT)
- Why sunblock in the U.S. is so much worse than in the E.U. (STAT)
- Trump’s science adviser calls for return to ‘gold-standard’ research to kickstart stalled advances (STAT)
- Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio (Endpoints)
- Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in funds (Endpoints)
- Exclusive: Weight loss startup Calibrate swaps CEOs in latest leadership shakeup (Endpoints)
- Exclusive: Optura raises $6.5M to help evaluate healthcare AI programs (Endpoints)
- Why Regeneron is buying 23andMe (Endpoints)
- Stelara biosimilars look to gain traction, helped by recent lessons from Humira (Endpoints)
- Boehringer Ingelheim’s late-stage data for lung disease candidate underwhelm some analysts (Endpoints)
- Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff (Endpoints)
- Weight-loss company Noom pivots to smaller doses of compounded Wegovy (Reuters)
- Exclusive: At-home screening startup Reperio Health raises $14M (Endpoints)
- Teal posts data on newly approved at-home cancer screening device (MedTech Dive)
- Women’s health faces growing headwinds, despite jump in venture investment (MedTech Dive)
- For Eisai and Biogen's Leqembi, first FDA-approved Alzheimer's blood test will take time to boost launch: analyst (Fierce Pharma)
- I study diet and chronic illness. Here’s the uncomfortable truth about seed oils (STAT)
- RFK Jr. calls for healthier school meals as Trump cancels program that funded them (Reuters)
- Common Fish Food Poisoning Types and Prevention Methods (Food Safety)
- CDC Provides Insights on 2023-2024 Salmonella Outbreak Linked to Charcuterie-Style Meats (Food Safety)
- The Man Who Built UnitedHealth Into an Industry Giant Now Has to Turn It Around (Bloomberg)
- Texas Isn’t Declaring a Measles Victory Yet (Bloomberg)
- Prescribing Red Flags: Pharmacists Be Wary of What the Doctor Orders (FDA Law Blog)
- When the FDA requires a large vaccine trial, who pays? (STAT)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
